GlaxoSmithKline, Shionogi and Pfizer scored a win Monday, and Gilead got a competitor, when the FDA approved the daily HIV medication dolutegravir. GSK & Co. submitted the drug via ViiV Healthcare, ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

These generic treatments have similar safety profiles to their reference products. The first generic versions of Truvada (emtricitabine, tenofovir disoproxil fumarate) and Atripla (efavirenz, ...

WASHINGTON, July 13 (UPI) -- Gilead could get a boost from the Food and Drug Administration's recent approval of Atripla, their triple combination pill for treating HIV infection, analysts said ...

To earn CME related to this news article, click here. January 16, 2009 — The US Food and Drug Administration (FDA) has approved revisions to the safety labeling to advise of the potential for ...

Armed with FDA approval for its triple HIV drug Triumeq, ViiV Healthcare can now start to challenge rival Gilead Sciences for a larger slice of the antiretroviral drugs market in the US. Triumeq ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

People infected with the virus that causes AIDS will soon be able to take a once-a-day pill that combines three drugs in a "cocktail" therapy that can be swallowed in a single dose. The pill, called ...

Gilead Sciences recently approved HIV drug Atripla could emerge as a top drug among new HIV patients, according to a new report from Prudential Equity Group. Gilead and Bristol-Myers Squibb announced ...

Gilead Sciences has been boosted by the results of a Phase III study showing that its four-drug HIV treatment was as effective as its top-selling drug Atripla, setting up a regulatory filing for the ...

Gilead Sciences Inc.’s four-in-one combination pill for AIDS was safer and more effective than its Atripla, the world’s top-selling HIV medicine, a study found. After 48 weeks, the ‘quad’ pill reduced ...

Merck & Co is seeking to register its three-in-one fixed dose combination Atripla in 66 developing countries, in addition to seeking World Health Organization prequalification for the product, the ...